Intel and Penn Medicine Announce Results of Largest Medical Federated Learning Study
05 Dezember 2022 - 05:00PM
Business Wire
Privacy-preserving AI technique enables
researchers to improve cancerous brain tumor detection by
33%.
What’s New: Intel Labs and the Perelman School of
Medicine at the University of Pennsylvania (Penn Medicine) have
completed a joint research study using federated learning – a
distributed machine learning (ML) artificial intelligence (AI)
approach – to help international healthcare and research
institutions identify malignant brain tumors. The largest medical
federated learning study to date with an unprecedented global
dataset examined from 71 institutions across six continents, the
project demonstrated the ability to improve brain tumor detection
by 33%.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20221205005170/en/
Using Intel federated learning technology
paired with Intel Software Guard Extensions (SGX), researchers were
able to address numerous data privacy concerns by keeping raw data
inside the data holders’ compute infrastructure and only allowing
model updates computed from that data to be sent to a central
server or aggregator, not the data itself. (Credit: Intel
Corporation)
“Federated learning has tremendous potential
across numerous domains, particularly within healthcare, as shown
by our research with Penn Medicine. Its ability to protect
sensitive information and data opens the door for future studies
and collaboration, especially in cases where datasets would
otherwise be inaccessible. Our work with Penn Medicine has the
potential to positively impact patients across the globe and we
look forward to continuing to explore the promise of federated
learning.” –Jason Martin, principal engineer, Intel Labs
Why It Matters: Data accessibility has long been an issue
in healthcare because of state and national data privacy laws,
including the Health Insurance Portability and Accountability Act
(HIPAA). Because of this, medical research and data sharing at
scale have been almost impossible to achieve without compromising
patient health information. Intel’s federated learning hardware and
software comply with data privacy concerns and preserve data
integrity, privacy and security through confidential computing.
The Penn Medicine-Intel result was accomplished by processing
high volumes of data in a decentralized system using Intel
federated learning technology paired with Intel® Software Guard
Extensions (SGX), which removes data-sharing barriers that have
historically prevented collaboration on similar cancer and disease
research. The system addresses numerous data privacy concerns by
keeping raw data inside the data holders’ compute infrastructure
and only allowing model updates computed from that data to be sent
to a central server or aggregator, not the data itself.
“All of the computing power in the world can’t do much without
enough data to analyze,” said Rob Enderle, principal analyst,
Enderle Group. “This inability to analyze data that has already
been captured has significantly delayed the massive medical
breakthroughs AI has promised. This federated learning study
showcases a viable path for AI to advance and achieve its potential
as the most powerful tool to fight our most difficult
ailments.”
Senior author Spyridon Bakas, PhD, assistant professor of
Pathology & Laboratory Medicine and Radiology at the Perelman
School of Medicine, said, “In this study, federated learning shows
its potential as a paradigm shift in securing multi-institutional
collaborations by enabling access to the largest and most diverse
dataset of glioblastoma patients ever considered in the literature,
while all data are retained within each institution at all times.
The more data we can feed into machine learning models, the more
accurate they become, which in turn can improve our ability to
understand and treat even rare diseases, such as glioblastoma.”
To advance the treatment of diseases, researchers must access
large amounts of medical data – in most cases, datasets that exceed
the threshold that one facility can produce. The research
demonstrates the effectiveness of federated learning at scale and
the potential benefits the healthcare industry can realize when
multisite data silos are unlocked. Benefits include early detection
of disease, which could improve quality of life or increase a
patient’s lifespan.
The results of the Penn Medicine-Intel Labs research were
published in the peer-reviewed journal, Nature Communications.
About the Research: In 2020, Intel and Penn Medicine
announced the agreement to cooperate and use federated learning to
improve tumor detection and improve treatment outcomes of a rare
form of cancer called glioblastoma (GBM), the most common and fatal
adult brain tumor with a median survival of just 14 months after
standard treatment. While treatment options have expanded over the
past 20 years, there has not been an improvement in overall
survival rates. The research was funded by the Informatics
Technology for Cancer Research program out of the National Cancer
Institute of the National Institutes of Health.
Penn Medicine and 71 international healthcare/research
institutions used Intel’s federated learning hardware and software
to improve the detection of rare cancer boundaries. A new
state-of-the-art AI software platform called Federated Tumor
Segmentation (FeTS) was used by radiologists to determine the
boundary of a tumor and improve the identification of the “operable
region” of tumors or “tumor core.” Radiologists annotated their
data and used open federated learning (OpenFL), an open source
framework for training machine learning algorithms, to run the
federated training. The platform was trained on 3.7 million images
from 6,314 GBM patients across six continents, the largest brain
tumor dataset to date.
What’s Next: Through this project, Intel Labs and Penn
Medicine have created a proof of concept for using federated
learning to gain knowledge from data. The solution can
significantly affect healthcare and other study areas, particularly
among other types of cancer research. Specifically, Intel developed
the OpenFL open source project to enable customers to adopt
real-world cross-silo federated learning and confidently deploy it
on Intel SGX. In addition, the novel FeTS initiative was
established as a collaborative network to provide a platform for
ongoing development and to encourage collaboration with the FeTS
platform and Intel’s OpenFL open source toolkit, both available on
GitHub.
More Context: Intel Works with the University of
Pennsylvania in Using Privacy-Preserving AI to Identify Brain
Tumors | Nature Communications Report | Intel and Penn Medicine
Announce Results of Largest Medical Federated Learning Study
(Video) | Secure Federated Learning for a Better World (Case Study)
| Intel, Penn Medicine Federated Learning Study (Quote Sheet)
Intel Customer Stories: Intel Customer Spotlight on
Intel.com | Customer Stories on Intel Newsroom
About Intel
Intel (Nasdaq: INTC) is an industry leader, creating
world-changing technology that enables global progress and enriches
lives. Inspired by Moore’s Law, we continuously work to advance the
design and manufacturing of semiconductors to help address our
customers’ greatest challenges. By embedding intelligence in the
cloud, network, edge and every kind of computing device, we unleash
the potential of data to transform business and society for the
better. To learn more about Intel’s innovations, go to
newsroom.intel.com and intel.com.
© Intel Corporation. Intel, the Intel logo and other Intel marks
are trademarks of Intel Corporation or its subsidiaries. Other
names and brands may be claimed as the property of others.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221205005170/en/
Laura Stadler 1-619-346-1170 laura.stadler@intel.com
Intel (NASDAQ:INTC)
Historical Stock Chart
Von Mär 2023 bis Apr 2023
Intel (NASDAQ:INTC)
Historical Stock Chart
Von Apr 2022 bis Apr 2023